HealthLinx LimitedABN 88 098 640 352576 Swan Street Richmond VIC...

HealthLinx Limited
ABN 88 098 640 352
576 Swan Street Richmond VIC 3121
Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
www.healthlinx.com.au
Prostate collaboration to continue with Garvan Institute
10 November 2011, Melbourne: HealthLinx Limited (ASX:HTX) and the Garvan Institute
of Medical Research have agreed to continue their research collaboration to include a
larger patient cohort following positive results from the initial study into prostate cancer.
The aim of the study was to assess the expression of proprietary HealthLinx biomarker/s
in plasma samples provided by the Garvan Institute and the relationship with
chemotherapy and overall survival for sufferers of prostate cancer.
Results from the initial study were promising to the point where the Garvan Institute and
HealthLinx have agreed to expand the collaboration in 2012 by analysing a larger patient
cohort as these samples become available.
“As predicted in the May announcement, results from the pilot studies became available
in the 3rd quarter this year however needed to be analysed and interpreted before release
to the market” explained HealthLinx managing director Nick Gatsios. “The company is
extremely pleased with the results to date and we are looking forward to the ongoing
collaboration with Garvan and the potential development of new markers to aid in
prostate cancer prognosis.”
According to the Australian Institute of Health and Welfare, prostate cancer is the most
common cancer diagnosed in Australia and the second greatest cause of cancer deaths in
men. The latest data shows that in 2010 almost 20,000 men were diagnosed with prostate
cancer. More than 3,300 men died as a direct cause of prostate cancer.